Enterprise Value

2.532B

Cash

337.5M

Avg Qtr Burn

N/A

Short % of Float

0.00%

Insider Ownership

14.68%

Institutional Own.

69.29%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
KIMMTRAK (Tebentafusp) (gp100) Details
Metastatic uveal melanoma, Cancer, Melanoma

Approved

Quarterly sales

Phase 2/3

Data readout

GSK01 (NY-ESO-1) Details
Cancer, Synovialsarcoma

Phase 1

Data readout

IMC-M113V Details
Viral infection, Human immunodeficiency virus

Phase 1

Data readout

IMC-C103C (MAGE-A4) Details
Ovarian cancer, Solid tumor/s, Head and neck cancer, Non-small cell lung carcinoma, Cancer, Gastric cancer

Phase 1

Data readout

IMC-F106C (PRAME) Details
Ovarian cancer, Solid tumor/s, Cancer, Breast cancer, Endometrial cancer

Phase 1

Data readout